An update about gRevlimid in an insightful article by BQ.
Natco expected to have 33% market share by fiscal 2015!
Source: Revlimid: The Star Drug In U.S. For Indian Pharma Companies — BQ Exclusive
| Subscribe To Our Free Newsletter |
Natco Pharma – Imminent Growth Cycle (?)
